Sara Kalman holds a Master’s degree in Molecular Biotechnology from the University of Heidelberg with a research focus on drug development involving projects at external research institutes such as EMBL and BioMedX. She joined the company in France in 2017 as a technical specialist with a focus on TFF and is since 2019 based out of Germany in her responsibility for managing MilliporeSigma’s excipient portfolio for liquid applications with a focus on protein-based therapeutics.